Innovations Maintain the Cold Chain

Published on: 
BioPharm International, BioPharm International-02-01-2019, Volume 32, Issue 2
Pages: 38–39

Recent advancements in cold-chain technology offer improved transporting and storing of temperature-sensitive pharmaceutical products.

As focus on the development and manufacture of biologics increases, so does the necessity for competent cold-chain technologies. Over the past several months, manufacturers have released an assortment of products and efforts to preserve the physical integrity of temperature-sensitive pharmaceutical products.

Pallet and parcel shipping systems

Softbox, a provider of temperature-control packaging solutions, released new pallet and parcel shipping systems that include the Tempcell ECO, Tempcell MAX, and Silverpod MAX (1).

The Tempcell ECO is a recyclable parcel shipper made from recycled corrugated paper materials. The ECO uses the company’s Thermaflute patent-pending design and is qualified against International Safe Transport Association (ISTA) 7D summer and winter profiles and is able to control different temperature ranges, including 0 °C to 30 °C products.

The Tempcell MAX is a single-use, high-performance phase change materials (PCM) parcel shipper that is qualified to ISTA 7D test profiles and maintains up to 96 hours of thermal protection. The MAX integrates the company’s SilverSkin radiant barrier to enhance thermal performance and uses next-generation recyclable Pharmacool MAX PCM coolants.

New to the company’s Silverpod pallet shipper range is the Silverpod MAX, a high-performance PCM pallet shipper that incorporates PCM coolants that enable safe storage before and during shipping. The Silverpad MAX also has a SilverSkin reflective radiant barrier for enhanced thermal performance and, like the Tempcell MAX, uses next-generation recyclable Pharmacool MAX PCM coolants.

The previously mentioned shipping solutions were showcased at the IQPC Temperature Controlled Logistics (TCL) conference in London on Jan. 28–31, 2019. Additionally, the company also pre-launched two temperature control packaging systems at TCL-the AEON Metro and Clinipod-for the delivery of pharmaceutical clinical trials.

AEON Metro is a reusable multi-drop delivery parcel shipper that enables cold-chain delivery without the need for temperature-controlled vehicles. The Metro has reusable PCM coolants that support up to 48 hours of multi-opening thermal protection. The Clinipod is a lightweight carry-home shipper built to facilitate the last-mile delivery of clinical trials to the end patient. Using the company’s reusable PCM coolants, it provides up to six hours of thermal protection in extreme temperature conditions.

Poseidon unleashes ‘Plug & Play’

Also presented at the 2019 installment of the TCL conference was progress on pharmaceutical ocean-freight network Poseidon’s ‘Plug & Play’ model (2). Poseidon is an industry reform initiative created to improve the conveyance of pharmaceutical products by ocean transport. The initiative includes an independent network of pharmaceutical manufacturers, specialist freight companies, and pharma logistics suppliers joining forces to improve cost, safety, and sustainability of the cold-chain process.

“Poseidon takes the form of a strategic supply network comprising a group of independent pharmaceutical manufacturers in conjunction with all the principal actors involved in transporting a pharma product by sea,” said Alan Kennedy, executive director at Poseidon, in a press statement. “Designed from the ground-up, it involves shippers, logistics companies, marine insurers, and product suppliers all being seated around the same table as equal partners. This up-front involvement of all the stakeholders helps create an environment of trust and teamwork.”

Advertisement

According to the Poseidon team, state-of-the-art thermal management and real-time shipment visibility are central elements in the Poseidon model, but what sets this initiative apart is its integrated approach, which brings together all cold-chain parties to collaboratively address fundamental problems in pharma logistics. The team also states that in addition to a standard full-container-load operation, Poseidon will be testing a flexible shared-container service in 2019 to cater for smaller consignments and provide maximum flexibility.

Dangerous temperature excursions are known to accompany cold-chain services and are often in violation of legislation surrounding the distribution of pharma products. “Pharmaceuticals are easily compromised, therapeutically, through temperature mis-management during transportation,” Kennedy explained in the release. “With its goal of zero temperature excursions, Poseidon aims to eliminate this risk through a restructure of the pharmaceutical cold-chain process to make it more efficient and reliable.”

Poseidon completed Phase I of a large-scale proof-of-concept pilot project in 2018 and is currently in Phase II. According to the Poseidon team, this field validation project aims to examine cold-chain processes, test-out protective packaging, and verify consignment visibility and data capture and is the largest pharma ocean freight project of its type ever conducted. The project involves the monitoring of several refrigerated container-loads of high-value pharmaceutical products during both summer and winter intercontinental logistics operations, including multiple ocean and overland stages.

Torben Weilmuenster, who has been elected to chair Poseidon’s governing management group and global head of Supply Chain Management at Merz Pharma GmbH & Co. KGaA, stated that 30 pharmaceutical companies and logistics providers are currently registered on the cloud-based Poseidon collaboration hub, including Merck & Co., Mylan, Novartis, Roche, and Johnson & Johnson (3).

 

Electronic data logger

The LOG-IC 360 Bluetooth Data Logger by American Thermal Instruments (ATI) provides accurate temperature and humidity readings along with safe, secure data retrieval and storage (4).

The data logger allows for remote temperature excursion (thermal alarm) monitoring during product transport. Less than two inches by three inches wide, the device can read individual temperatures up to 300 feet from the unopened product. The lithium coin cell battery has a minimum one-year capacity, a temperature range of -20 °C to 70 °C, and relays data to Android, iOS, or any other Bluetooth-enabled device. 

High-precision temperature accuracy is ± 0.25 °C, compared to other industry suppliers at ± 0.50 °C, the company reports. The logger tracks a humidity range of 0–80% relative humidity with communication certifications, which include Federal Communications Commission, Conformité Européenne (CE), and National Institute of Standards and Technology platforms.

“At the very beginning stages of product development, we put a priority on the various needs of our customers,” said Rob Snyder, technology director of ATI, in a press release. “We plan to advance the technology as fixed asset monitoring with our added app technology. The LOG-IC 360 BT features an easy-to-read LCD screen, is programmable for up to four distinct alarms, and is scalable for temperature/humidity readings.”

Data can be viewed using ATI’s DataNow Cloud service and mobile applications. Any excursions will display when and for how long the product was not in range of acceptable temperature and humidity levels, aiding to verify compliance with US regulatory bodies such as FDA, according to the company.  

References

1. Softbox, “Softbox Announces the Launch of New Innovative Temperature Control Packaging Systems,” Press Release, Jan. 24, 2019.
2. Poseidon, “Poseidon Exposing its Unique Plug & Play Pharma Ocean-Freight Model in London,” Press Release, Jan. 14, 2019.
3. Poseidon, “Participant Shippers as at Feb 2019,” www.poseidon.team, accessed on Jan. 31, 2019.
4. American Thermal Instruments, “ATI Launches Innovative Electronic Data Logger for Cold Chain System,” Press Release, Sept. 18, 2018. 

Article Details

BioPharm International
Vol. 32, No. 2
February 2019
Pages: 38–39

Citation

When referring to this article, please cite it as A. Lowry, “Innovations Maintain the Cold Chain," BioPharm International 32 (2) 2019.